Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cellceutix has entered into a laboratory services research support agreement with Dana Farber/Partners CancerCare.
Subscribe to our email newsletter
The agreement allows the companies to support for the planned clinical trials of a cancer drug – Kevetrin.
Cellceutix develops drugs to treat preclinical cancer, anti-inflammatory and autism.
Cellceutix other drug include KM-391to treat autism and KM-133 to treat psoriasis.